The discovery of 2-amino-3,5-diarylbenzamide inhibitors of IKK-α and IKK-β kinases

被引:60
作者
Christopher, John A.
Avitabile, Barbara G.
Bamborough, Paul
Champigny, Aurelie C.
Cutler, Geoffrey J.
Dyos, Susan L.
Grace, Ken G.
Kerns, Jeffrey K.
Kitson, Jeremy D.
Mellor, Geoffrey W.
Morey, James V.
Morse, Mary A.
O'Malley, Carolyn F.
Patel, Champa B.
Probst, Nicholas
Rumsey, William
Smith, Clive A.
Wilson, Michael J.
机构
[1] GlaxoSmithKline R&D, Med Res Ctr, Stevenage SG1 2NY, Herts, England
[2] GlaxoSmithKline R&D, Harlow CM19 5AW, Essex, England
[3] GlaxoSmithKline Inc, King Of Prussia, PA 19406 USA
关键词
kinase; IKK; inhibitor;
D O I
10.1016/j.bmcl.2007.04.088
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A potent and selective series of 2-amino-3,5-diarylbenzamide inhibitors of IKK-alpha and IKK-beta is described. The most potent compounds are 8h, 8r and 8v, with IKK-beta inhibitory potencies of pIC(50) 7.0, 6.8 and 6.8, respectively. The series has excellent selectivity, both within the IKK family over IKK-epsilon, and across a wide variety of kinase assays. The potency of 8h in the IKK-beta enzyme assay translates to significant cellular activity (pIC(50) 5.7-6.1) in assays of functional and mechanistic relevance. (C) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3972 / 3977
页数:6
相关论文
共 16 条
[1]   Imidazo[1,2-a]pyridines:: A potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisation [J].
Anderson, M ;
Beattie, JF ;
Breault, GA ;
Breed, J ;
Byth, KF ;
Culshaw, JD ;
Ellston, RPA ;
Green, S ;
Minshull, CA ;
Norman, RA ;
Pauptit, RA ;
Stanway, J ;
Thomas, AP ;
Jewsbury, PJ .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (18) :3021-3026
[2]  
[Anonymous], SCI STKE
[3]   Pentafluorophenyl sulfonate ester as a protecting group for the preparation of biaryl- and heterobiaryl sulfonate esters [J].
Avitabile, BG ;
Smith, CA ;
Judd, DB .
ORGANIC LETTERS, 2005, 7 (05) :843-846
[4]   5-(1H-benzimidazol-1-yl)-3-alkoxy-2-thiophenecarbonitriles as potent, selective, inhibitors of IKK-ε kinase [J].
Bamborough, Paul ;
Christopher, John A. ;
Cutler, Geoffrey J. ;
Dickson, Marion C. ;
Mellor, Geoffrey W. ;
Morey, James V. ;
Patel, Champa B. ;
Shewchuk, Lisa M. .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (24) :6236-6240
[5]   The two NF-κB activation pathways and their role in innate and adaptive immunity [J].
Bonizzi, G ;
Karin, M .
TRENDS IN IMMUNOLOGY, 2004, 25 (06) :280-288
[6]   Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): Design, synthesis, enzymatic activities, and X-ray crystallographic analysis [J].
Bramson, HN ;
Corona, J ;
Davis, ST ;
Dickerson, SH ;
Edelstein, M ;
Frye, SV ;
Gampe, RT ;
Harris, PA ;
Hassell, A ;
Holmes, WD ;
Hunter, RN ;
Lackey, KE ;
Lovejoy, B ;
Luzzio, MJ ;
Montana, V ;
Rocque, WJ ;
Rusnak, D ;
Shewchuk, L ;
Veal, JM ;
Walker, DH ;
Kuyper, LF .
JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (25) :4339-4358
[7]   Direct synthesis of sulfonamides and activated sulfonate esters from sulfonic acids [J].
Caddick, S ;
Wilden, JD ;
Judd, DB .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2004, 126 (04) :1024-1025
[8]   A new route to sulfonamides via intermolecular radical addition to pentafluorophenyl vinylsulfonate and subsequent aminolysis [J].
Caddick, S ;
Wilden, JD ;
Bush, HD ;
Wadman, SN ;
Judd, DB .
ORGANIC LETTERS, 2002, 4 (15) :2549-2551
[9]   Small molecule inhibitors of IKK kinase activity [J].
Coish, PDG ;
Wickens, PL ;
Lowinger, TB .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2006, 16 (01) :1-12
[10]   Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor [J].
Davies, TG ;
Bentley, J ;
Arris, CE ;
Boyle, FT ;
Curtin, NJ ;
Endicott, JA ;
Gibson, AE ;
Golding, BT ;
Griffin, RJ ;
Hardcastle, IR ;
Jewsbury, P ;
Johnson, LN ;
Mesguiche, V ;
Newell, DR ;
Noble, MEM ;
Tucker, JA ;
Wang, L ;
Whitfield, HJ .
NATURE STRUCTURAL BIOLOGY, 2002, 9 (10) :745-749